35998-29-9|HBED|2,2'-(ethane-1,2-diylbis((2-hydroxybenzyl)azanediyl))diacetic acid|-范德生物科技公司

HBED

NMR下载 COA and HPLC MSDS下载
names：
2,2'-(ethane-1,2-diylbis((2-hydroxybenzyl)azanediyl))diacetic acid
CAS号：
35998-29-9
MDL Number：
MF(分子式)： C20H24N2O6 MW(分子量)： 388.42
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	HBED
英文别名	HBED; CHEL II; CHEL-II; CHELII;
CAS号	35998-29-9
Inchi	InChI=1S/C20H24N2O6/c23-17-7-3-1-5-15(17)11-21(13-19(25)26)9-10-22(14-20(27)28)12-16-6-2-4-8-18(16)24/h1-8,23-24H,9-14H2,(H,25,26)(H,27,28)
InchiKey	GRUVVLWKPGIYEG-UHFFFAOYSA-N
分子式 Formula	C20H24N2O6
分子量 Molecular Weight	388.42
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	HBED(CAS:35998-29-9):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	HBED is an iron chelator used for treatment of chronic iron overload and acute iron poisoning.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Cuccurullo V, Di Stasio GD, Mansi L. Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers. World J Nucl Med. 2018 Apr-Jun;17(2):70-78. doi: 10.4103/wjnm.WJNM_54_17. Review. PubMed PMID: 29719480; PubMed Central PMCID: PMC5905261.

[2]Bailey J, Piert M. Performance of (68)Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence. Curr Urol Rep. 2017 Sep 9;18(11):84. doi: 10.1007/s11934-017-0736-1. Review. PubMed PMID: 28889366.

[3] von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. (68)Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2016 Nov 15. pii: S2405-4569(16)30160-2. doi: 10.1016/j.euf.2016.11.002. [Epub ahead of print] Review. PubMed PMID: 28753806.

[4] Knorr K, Eiber M, Maurer T, Wester HJ, Scheidhauer K. [PET-CT and PET-MRI of the prostate : From (18)F-FDG to (68)Ga-PSMA]. Radiologe. 2017 Aug;57(8):631-636. doi: 10.1007/s00117-017-0276-1. Review. German. PubMed PMID: 28688023.

[5] Fitzpatrick C, Lynch O, Marignol L. (68)Ga-PSMA-PET/CT Has a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease. Anticancer Res. 2017 Jun;37(6):2753-2760. Review. PubMed PMID: 28551611.

6: Michaud L, Touijer KA. Molecular imaging for prostate cancer: Performance analysis of (68)Ga-PSMA PET/CT versus choline PET/CT. Actas Urol Esp. 2017 Jun;41(5):292-299. doi: 10.1016/j.acuro.2016.09.015. Epub 2016 Nov 30. Review. English, Spanish. PubMed PMID: 27912910.7: Rauscher I, Eiber M, Jilg CA, Gschwend JE, Maurer T. [PSMA-radioguided surgery in localized recurrent prostate cancer : Current and future aspects]. Urologe A. 2017 Jan;56(1):18-23. doi: 10.1007/s00120-016-0275-2. Review. German. PubMed PMID: 27885455.8: Schreiter V, Reimann C, Geisel D, Schreiter NF. Nuclear Medicine Imaging of Prostate Cancer. Rofo. 2016 Nov;188(11):1037-1044. Epub 2016 Jun 14. Review. PubMed PMID: 27299668.9: Incerti E, Mapelli P, Gianolli L, Picchio M. PET imaging for lymph node dissection in prostate cancer. World J Urol. 2017 Apr;35(4):507-515. doi: 10.1007/s00345-016-1954-8. Epub 2016 Oct 17. Review. PubMed PMID: 27752756.10: Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer. Semin Nucl Med. 2016 Sep;46(5):405-18. doi: 10.1053/j.semnuclmed.2016.04.004. Review. PubMed PMID: 27553466.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开